Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in Idiopathic Intracranial Hypertension.

Olivia GrechJames L MitchellHannah S LyonsAndreas YiangouMark ThallerGeorgios TsermoulasKristian BrockMiss Susan P Mollan Alexandra Jean Sinclair

Published in: Eye (London, England) (2024)

In patients with raised ICP due to IIH, exenatide, a drug emerging as an ICP lowering agent, does not adversely impact cognition. This is encouraging and has potential to be relevant when considering prescribing choices to lower ICP.

Keyphrases

mild cognitive impairment
blood pressure
white matter
primary care
adverse drug
emergency department
human health
risk assessment
climate change
drug induced